Drug Hunter
Home > M3814
DNA-PK-selective kinase inhibitor
oral efficacy in xenograft radiation models
undisclosed screening and optimization
Mol. Cancer Ther., Mar. 27, 2020
Merck KGaA, Darmstadt, DE
M3814 (Merck KGaA oral DNA-PK selective kinase inhibitor)
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
March 2020
Molecules of the Month
01
January
02
February
03
March
04
April
05
May
06
June
07
July
08
August
09
September
10
October
11
November
12
December
MOTY Nominees
Molecule of the Year